DOI QR코드

DOI QR Code

Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues

  • Sang Hyuk Kim (Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Ji-Yong Moon (Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Kyung Hoon Min (Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Hyun Lee (Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine)
  • Received : 2023.12.15
  • Accepted : 2024.02.02
  • Published : 2024.07.31

Abstract

The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) revised the definition of chronic obstructive pulmonary disease (COPD) to broadly include a variety of etiologies. A new taxonomy, composed of etiotypes, aims to highlight the heterogeneity in causes and pathogenesis of COPD, allowing more personalized management strategies and emphasizing the need for targeted research to understand and manage COPD better. However, controversy arises with including some diseases under the umbrella term of COPD, as their clinical presentations and treatments differ from classical COPD, which is smoking-related. COPD due to infection (COPD-I) and COPD due to environmental exposure (COPD-P) are classifications within the new taxonomy. Some disease entities in these categories show distinct clinical features and may not benefit from conventional COPD treatments, raising questions about their classification as COPD subtypes. There is also controversy regarding whether bronchiectasis with airflow limitations should be classified as an etiotype of COPD. This article discusses controversial issues associated with the proposed etiotypes for COPD in terms of COPD-I, COPD-P, and bronchiectasis. While the updated COPD definition by GOLD 2023 is a major step towards recognizing the disease's complexity, it also raises questions about the classification of related respiratory conditions. This highlights the need for further research to improve our understanding and approach to COPD management.

Keywords

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report [Internet]. Fontana: GOLD; 2023 [cited 2024 Feb 16]. Available from: http://goldcopd.org/2023-gold-report-2.
  2. Choi JY, Rhee CK. Diagnosis and treatment of early chronic obstructive lung disease (COPD). J Clin Med 2020;9:3426.
  3. Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022;400:921-72. https://doi.org/10.1016/S0140-6736(22)01273-9
  4. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65. https://doi.org/10.1111/j.1440-1843.2011.01951.x
  5. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022;10:447-58. https://doi.org/10.1016/S2213-2600(21)00511-7
  6. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, et al. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax 2018;73:414-21. https://doi.org/10.1136/thoraxjnl-2017-210722
  7. Sarkar C, Zhang B, Ni M, Kumari S, Bauermeister S, Gallacher J, et al. Environmental correlates of chronic obstructive pulmonary disease in 96 779 participants from the UK Biobank: a cross-sectional, observational study. Lancet Planet Health 2019;3:e478-90. https://doi.org/10.1016/S2542-5196(19)30214-1
  8. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet 2022;399:2227-42. https://doi.org/10.1016/S0140-6736(22)00470-6
  9. Lee H, Shin SH, Park HY, Lim SY. Can we call all obstructive lung diseases COPD? Eur Respir J 2023;61:2300462.
  10. Terzikhan N, Verhamme KM, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. Eur J Epidemiol 2016;31:785-92. https://doi.org/10.1007/s10654-016-0132-z
  11. O'Donnell AE. Bronchiectasis: a clinical review. N Engl J Med 2022;387:533-45. https://doi.org/10.1056/NEJMra2202819
  12. Moon SM, Choi H, Kang HK, Lee SW, Sim YS, Park HY, et al. Impacts of asthma in patients with bronchiectasis: findings from the KMBARC Registry. Allergy Asthma Immunol Res 2023;15:83-93. https://doi.org/10.4168/aair.2023.15.1.83
  13. Kim SH, Kim C, Jeong I, Lee SJ, Kim TH, Lee CY, et al. Chronic obstructive pulmonary disease is associated with decreased quality of life in bronchiectasis patients: findings from the KMBARC Registry. Front Med (Lausanne) 2021;8:722124.
  14. Hurst JR, Elborn JS, De Soyza A; BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J 2015;45:310-3. https://doi.org/10.1183/09031936.00170014
  15. Marsland I, Sobala R, De Soyza A, Witham M. Multimorbidity in bronchiectasis: a systematic scoping review. ERJ Open Res 2023;9:00296-2022.
  16. Kim SH, Lee H, Kim Y. Health-related quality of life after pulmonary tuberculosis in South Korea: analysis from the Korea National Health and Nutrition Examination Survey between 2010 and 2018. Health Qual Life Outcomes 2021;19:195.
  17. Agusti A, Anzueto A, Celli BR, Mortimer K, Salvi S, Vogelmeier CF, et al. GOLD 2023 executive summary: responses from the GOLD Scientific Committee. Eur Respir J 2023;61:2300616.
  18. Higham A, Quinn AM, Cancado JE, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res 2019;20:49.
  19. Akatli AN, Ulutas H, Turkmen Samdanci E, Celik MR. Bronchiectasis: retrospective analysis of clinical and pathological findings in a tertiary-care hospital. Int J Clin Pract 2022;2022:8773204.
  20. Borekci S, Gundogdu S, Harbiyeli DO, Musellim B. Annual FEV1 loss in patients with noncystic fibrosis bronchiectasis and affecting factors. South Med J 2022;115:328-32. https://doi.org/10.14423/SMJ.0000000000001394
  21. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017;195:1384-93. https://doi.org/10.1164/rccm.201605-1027OC
  22. Dhar R, Singh S, Talwar D, Murali Mohan BV, Tripathi SK, Swarnakar R, et al. Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. Eur Respir J 2023;61:2200611.
  23. Kim NY, Lee CH, Jin KN, Lee HW, Heo EY, Kim DK, et al. Clinical deterioration and lung function change in patients with concomitant asthma and bronchiectasis. J Allergy Clin Immunol Pract 2022;10:2607-13. https://doi.org/10.1016/j.jaip.2022.05.026
  24. Martinez-Garcia MA, Oscullo G, Posadas T, Zaldivar E, Villa C, Dobarganes Y, et al. Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. Clin Microbiol Infect 2021;27:428-34. https://doi.org/10.1016/j.cmi.2020.04.007
  25. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-72. https://doi.org/10.1378/chest.07-0490
  26. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50:1700629.
  27. Jayaram L, Vandal AC, Chang CL, Lewis C, Tong C, Tuffery C, et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J 2022;59:2102184.
  28. Jeong HJ, Lee H, Carriere KC, Kim JH, Han JH, Shin B, et al. Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int J Chron Obstruct Pulmon Dis 2016;11:2757-64. https://doi.org/10.2147/COPD.S115581
  29. Lee SY, Lee JS, Lee SW, Oh YM. Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. J Thorac Dis 2021;13:169-77. https://doi.org/10.21037/jtd-20-1282
  30. Morton M, Wilson N, Homer TM, Simms L, Steel A, Maier R, et al. Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis. BMJ Open 2023;13:e071906.
  31. Cazzola M, Martinez-Garcia MA, Matera MG. Bronchodilators in bronchiectasis: there is light but it is still too dim. Eur Respir J 2022;59:2103127.
  32. Martinez-Garcia MA. Bronchodilators in bronchiectasis: we urgently need more trials. Lung 2023;201:5-7. https://doi.org/10.1007/s00408-023-00600-2
  33. Choi JY. Time to prescribe dual instead of mono. Tuberc Respir Dis (Seoul) 2021;84:252-3. https://doi.org/10.4046/trd.2021.0030
  34. Park YB, Lee JH, Ra SW, Park HY, Jung JY, Kang YA, et al Definitions of chronic obstructive pulmonary disease and chronic obstructive pulmonary disease exacerbation: a modified Delphi survey. Tuberc Respir Dis (Seoul) 2023;86:196-202. https://doi.org/10.4046/trd.2023.0014
  35. Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One 2016;11:e0150532.
  36. Traversi L, Miravitlles M, Martinez-Garcia MA, Shteinberg M, Bossios A, Dimakou K, et al. ROSE: radiology, obstruction, symptoms and exposure: a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res 2021;7:00399-2021. https://doi.org/10.1183/23120541.00399-2021
  37. Rhee CK, Yoo KH, Lee JH, Park MJ, Kim WJ, Park YB, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis 2013;17:67-75. https://doi.org/10.5588/ijtld.12.0351
  38. Ivanova O, Hoffmann VS, Lange C, Hoelscher M, Rachow A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur Respir Rev 2023;32:220221.
  39. Fan H, Wu F, Liu J, Zeng W, Zheng S, Tian H, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Transl Med 2021;9:390.
  40. Kim SH, Lee H, Kim Y, Rhee CK, Min KH, Hwang YI, et al. Recent prevalence of and factors associated with chronic obstructive pulmonary disease in a rapidly aging society: Korea National Health and Nutrition Examination Survey 2015-2019. J Korean Med Sci 2023;38:e108.
  41. Moon SM, Lim JH, Hong YS, Shin KC, Lee CY, Kim DJ, et al. Clinical impact of forced vital capacity on exercise performance in patients with chronic obstructive pulmonary disease. J Thorac Dis 2021;13:837-46. https://doi.org/10.21037/jtd-20-1098a
  42. Choi H, Han K, Jung JH, Park SH, Kim SH, Kang HK, et al. Long-term mortality of tuberculosis survivors in Korea: a population-based longitudinal study. Clin Infect Dis 2023;76:e973-81. https://doi.org/10.1093/cid/ciac411
  43. Moon SM, Choi H, Kim SH, Kang HK, Park DW, Jung JH, et al. Increased lung cancer risk and associated risk factors in tuberculosis survivors: a Korean population-based study. Clin Infect Dis 2023;77:1329-39. https://doi.org/10.1093/cid/ciad373
  44. Jung JW, Choi JC, Shin JW, Kim JY, Choi BW, Park IW. Pulmonary impairment in tuberculosis survivors: the Korean National Health and Nutrition Examination Survey 2008-2012. PLoS One 2015;10:e0141230.
  45. Lam KB, Jiang CQ, Jordan RE, Miller MR, Zhang WS, Cheng KK, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010;137:593-600. https://doi.org/10.1378/chest.09-1435
  46. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007;30:1180-5. https://doi.org/10.1183/09031936.00083507
  47. Wang Y, Li Z, Li F. Impact of previous pulmonary tuberculosis on chronic obstructive pulmonary disease: baseline results from a prospective cohort study. Comb Chem High Throughput Screen 2023;26:93-102. https://doi.org/10.2174/1386207325666220406111435
  48. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989;83:195-8.
  49. Ross J, Ehrlich RI, Hnizdo E, White N, Churchyard GJ. Excess lung function decline in gold miners following pulmonary tuberculosis. Thorax 2010;65:1010-5. https://doi.org/10.1136/thx.2009.129999
  50. Silva DR, Freitas AA, Guimaraes AR, D'Ambrosio L, Centis R, Munoz-Torrico M, et al. Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. J Bras Pneumol 2022;48:e20210515.
  51. Leem AY, Park B, Kim YS, Chang J, Won S, Jung JY. Longitudinal decline in lung function: a community-based cohort study in Korea. Sci Rep 2019;9:13614.
  52. Park HJ, Byun MK, Kim HJ, Ahn CM, Kim DK, Kim YI, et al. History of pulmonary tuberculosis affects the severity and clinical outcomes of COPD. Respirology 2018;23:100-6. https://doi.org/10.1111/resp.13147
  53. Allwood BW, Rigby J, Griffith-Richards S, Kanarek D, du Preez L, Mathot B, et al. Histologically confirmed tuberculosis-associated obstructive pulmonary disease. Int J Tuberc Lung Dis 2019;23:552-4. https://doi.org/10.5588/ijtld.18.0722
  54. Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, et al. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study. Int J Chron Obstruct Pulmon Dis 2017;12:1589-96. https://doi.org/10.2147/COPD.S128750
  55. Kim HC, Kim TH, Rhee CK, Han M, Oh YM. Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation. Ther Clin Risk Manag 2019;15:377-87. https://doi.org/10.2147/TCRM.S194324
  56. Kim HC, Kim TH, Kim YJ, Rhee CK, Oh YM. Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea. Respir Res 2019;20:85.
  57. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol 2020;11:303.
  58. Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest 2016;150:1222-32. https://doi.org/10.1016/j.chest.2016.06.005
  59. Kim HO, Lee K, Choi HK, Ha S, Lee SM, Seo GH. Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea. Medicine (Baltimore) 2019;98:e17869.
  60. Lee SW, Park Y, Kim S, Chung EK, Kang YA. Comorbidities of nontuberculous mycobacteria infection in Korean adults: results from the National Health Insurance Service-National Sample Cohort (NHIS-NSC) database. BMC Pulm Med 2022;22:283.
  61. Uno S, Asakura T, Morimoto K, Yoshimura K, Uwamino Y, Nishimura T, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med 2020;20:262.
  62. Zabost AT, Szturmowicz M, Brzezinska SA, Klatt MD, Augustynowicz-Kopec EM. Mycobacterium chimaera as an underestimated cause of NTM lung diseases in patients hospitalized in pulmonary wards. Pol J Microbiol 2021;70:315-20. https://doi.org/10.33073/pjm-2021-028
  63. Glodic G, Samarzija M, Sabol I, Bulat Kardum L, Carevic Vladic V, Dzubur F, et al. Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia. Wien Klin Wochenschr 2021;133:1195-200. https://doi.org/10.1007/s00508-021-01923-x
  64. Hu C, Huang L, Cai M, Wang W, Shi X, Chen W. Characterization of non-tuberculous mycobacterial pulmonary disease in Nanjing district of China. BMC Infect Dis 2019;19:764.
  65. Zhang ZX, Cherng BP, Sng LH, Tan YE. Clinical and microbiological characteristics of non-tuberculous mycobacteria diseases in Singapore with a focus on pulmonary disease, 2012-2016. BMC Infect Dis 2019;19:436.
  66. Kim JH, Seo KW, Shin Y, Oh JS, Jun JB, Jeong J, et al. Risk factors for developing Mycobacterium kansasii lung disease: a case-control study in Korea. Medicine (Baltimore) 2019;98:e14281.
  67. Carneiro MD, Nunes LS, David SM, Dias CF, Barth AL, Unis G. Nontuberculous mycobacterial lung disease in a high tuberculosis incidence setting in Brazil. J Bras Pneumol 2018;44:106-11. https://doi.org/10.1590/s1806-37562017000000213
  68. Osmani M, Sotello D, Alvarez S, Odell JA, Thomas M. Mycobacterium abscessus infections in lung transplant recipients: 15-year experience from a single institution. Transpl Infect Dis 2018;20:e12835.
  69. Huang HL, Cheng MH, Lu PL, Shu CC, Wang JY, Wang JT, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan: a retrospective, five-year multicenter study. Sci Rep 2017;7:16300.
  70. Liao TL, Lin CF, Chen YM, Liu HJ, Chen DY. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case-control study in a TB endemic area. Sci Rep 2016;6:29443.
  71. Fujita K, Ito Y, Hirai T, Kubo T, Togashi K, Ichiyama S, et al. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res 2014;1:e000050.
  72. de Mello KG, Mello FC, Borga L, Rolla V, Duarte RS, Sampaio EP, et al. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011. Emerg Infect Dis 2013;19:393-9.
  73. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-82. https://doi.org/10.1164/rccm.201003-0503OC
  74. Pyarali FF, Schweitzer M, Bagley V, Salamo O, Guerrero A, Sharifi A, et al. Increasing non-tuberculous mycobacteria infections in veterans with COPD and association with increased risk of mortality. Front Med (Lausanne) 2018;5:311.
  75. Huang CT, Tsai YJ, Wu HD, Wang JY, Yu CJ, Lee LN, et al. Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2012;16:539-45. https://doi.org/10.5588/ijtld.11.0412
  76. Kobayashi T, Tsuyuguchi K, Arai T, Tsuji T, Maekura T, Kurahara Y, et al. Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: a retrospective study. J Clin Tuberc Other Mycobact Dis 2018;11:17-21. https://doi.org/10.1016/j.jctube.2018.02.002
  77. Lee MR, Yang CY, Chang KP, Keng LT, Yen DH, Wang JY, et al. Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS One 2013;8:e58214.
  78. Park HJ, Kim JY, Kim HJ, Yim JJ, Kwak N. Lung function decline in non-tuberculous mycobacterial pulmonary disease according to disease severity. Int J Tuberc Lung Dis 2023;27:465-70. https://doi.org/10.5588/ijtld.22.0616
  79. Choi S, Potts KJ, Althoff MD, Jimenez G, Bai X, Calhoun KM, et al. Histopathologic analysis of surgically resected lungs of patients with non-tuberculous mycobacterial lung disease: a retrospective and hypothesis-generating study. Yale J Biol Med 2021;94:527-35.
  80. Kubo K, Yamazaki Y, Masubuchi T, Takamizawa A, Yamamoto H, Koizumi T, et al. Pulmonary infection with Mycobacterium avium-intracellulare leads to air trapping distal to the small airways. Am J Respir Crit Care Med 1998;158:979-84. https://doi.org/10.1164/ajrccm.158.3.9802042
  81. Bai S, Zhao L. Imbalance between injury and defense in the COPD emphysematous phenotype. Front Med (Lausanne) 2021;8:653332.
  82. Kurz SG, Zha BS, Herman DD, Holt MR, Daley CL, Ruminjo JK, et al. Summary for clinicians: 2020 clinical practice guideline summary for the treatment of nontuberculous mycobacterial pulmonary disease. Ann Am Thorac Soc 2020;17:1033-9. https://doi.org/10.1513/AnnalsATS.202003-222CME
  83. Kumar K, Daley CL, Griffith DE, Loebinger MR. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev 2022;31:210212.
  84. van Ingen J, Aksamit T, Andrejak C, Bottger EC, Cambau E, Daley CL, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J 2018;51:1800170.
  85. Chung MP, Lee KS, Han J, Kim H, Rhee CH, Han YC, et al. Bronchial stenosis due to anthracofibrosis. Chest 1998;113:344-50. https://doi.org/10.1378/chest.113.2.344
  86. Kim YJ, Jung CY, Shin HW, Lee BK. Biomass smoke induced bronchial anthracofibrosis: presenting features and clinical course. Respir Med 2009;103:757-65. https://doi.org/10.1016/j.rmed.2008.11.011
  87. Kim H, Cha SI, Shin KM, Lim JK, Oh S, Kim MJ, et al. Clinical relevance of bronchial anthracofibrosis in patients with chronic obstructive pulmonary disease exacerbation. Tuberc Respir Dis (Seoul) 2014;77:124-31. https://doi.org/10.4046/trd.2014.77.3.124
  88. Jang SJ, Lee SY, Kim SC, Lee SY, Cho HS, Park KH, et al. Clinical and radiological characteristics of non-tuberculous bronchial anthracofibrosis. Tuberc Respir Dis 2007;63:139-44. https://doi.org/10.4046/trd.2007.63.2.139
  89. Jung SW, Kim YJ, Kim GH, Kim MS, Son HS, Kim JC, et al. Ventilatory dynamics according to bronchial stenosis in bronchial anthracofibrosis. Tuberc Respir Dis 2005;59:368-73. https://doi.org/10.4046/trd.2005.59.4.368
  90. Ucar EY, Araz O, Akgun M, Meral M, Saglam L, Kaynar H, et al. Bronchial anthracosis-anthracofibrosis: potential causes and clinical characteristics. Eurasian J Pulmonol 2014;16:17-20. https://doi.org/10.5152/ejp.2014.72681
  91. Amoli K. Anthracotic airways disease: report of 102 cases. Tanaffos 2009;8:14-22.
  92. El Raouf BA, Kramer MR, Fruchter O. Bronchial anthracofibrosis: treatment using airway stents. Int J Tuberc Lung Dis 2013;17:1118-20. https://doi.org/10.5588/ijtld.13.0116
  93. Jamaati H, Sharifi A, Mirenayat MS, Mirsadraee M, Amoli K, Heidarnazhad H, et al. What do we know about anthracofibrosis?: a literature review. Tanaffos 2017;16:175-89.
  94. Mirsadraee M, Ghaffari S, Saeedi P. Effect of salmeterol-fluticasone combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis: a double blind randomized, cross over, placebo controlled, clinical trial. Tanaffos 2018;17:163-71.
  95. Peng Y, Li X, Cai S, Chen Y, Dai W, Liu W, et al. Prevalence and characteristics of COPD among pneumoconiosis patients at an occupational disease prevention institute: a cross-sectional study. BMC Pulm Med 2018;18:22.
  96. Weissman DN. Progressive massive fibrosis: an overview of the recent literature. Pharmacol Ther 2022;240:108232.
  97. Perlman DM, Maier LA. Occupational lung disease. Med Clin North Am 2019;103:535-48. https://doi.org/10.1016/j.mcna.2018.12.012